Cyclooxygenase-2 Inhibition Increases Mortality, Enhances Left Ventricular Remodeling, and Impairs Systolic Function After Myocardial Infarction in the Pig

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Circulation

• Publication date

  2007-01-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.106.647230PMID 17210840
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention

  2006cited by this paper
• Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice.

  2005cited by this paper
• Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.

  2005cited by this paper
• Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2–dependent mechanisms

  2005cited by this paper
• Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.

  2005cited by this paper
• Impact of Prolonged Cyclooxygenase-2 Inhibition on Inflammatory Markers and Endothelial Function in Patients With Ischemic Heart Disease and Raised C-Reactive Protein: A Randomized Placebo-Controlled Study

  2004cited by this paper
• Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse.

  2004cited by this paper
• Cyclooxygenase-2 Inhibitor Treatment Improves Left Ventricular Function and Mortality in a Murine Model of Doxorubicin-Induced Heart Failure

  2004cited by this paper
• Ionic-liquid matrices for quantitative analysis by MALDI-TOF mass spectrometry

  2004cited by this paper
• Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe?

  2004cited by this paper
• Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study.

  2003cited by this paper
• Selective COX-2 Inhibition Improves Endothelial Function in Coronary Artery Disease

  2003cited by this paper
• Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib.

  2003cited by this paper
• Cyclooxygenase-2 Promotes Early Atherosclerotic Lesion Formation in LDL Receptor–Deficient Mice

  2002cited by this paper
• Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning.

  2002cited by this paper
• Cyclooxygenase-2 and atherosclerosis

  2002cited by this paper
• Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.

  2002cited by this paper
• Cyclooxygenase-1 and -2 Knockout Mice Demonstrate Increased Cardiac Ischemia/Reperfusion Injury but Are Protected by Acute Preconditioning

  2001cited by this paper
• Hypertonic saline method accurately determines parallel conductance for dual-field conductance catheter.

  2001cited by this paper
• Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

  2000cited by this paper
• Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction.

  2000cited by this paper
• Evidence for an essential role of cyclooxygenase-2 as a mediator of the late phase of ischemic preconditioning in mice

  2000cited by this paper
• Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

  2000cited by this paper
• Effects of critical coronary stenosis on global systolic left ventricular function quantified by pressure-volume relations during dobutamine stress in the canine heart.

  1998cited by this paper
• Relation of initial infarct size to extent of left ventricular remodeling in the year after acute myocardial infarction.

  1995cited by this paper
• Chronic aspirin treatment affects collagen deposition in non-infarcted myocardium during remodeling after coronary artery ligation in the rat.

  1995cited by this paper
• Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications

  1990cited by this paper
• Drug-induced expansion of infarct: morphologic and functional correlations.

  1984cited by this paper
• Continuous measurement of left ventricular volume in animals and humans by conductance catheter.

  1984cited by this paper
• Indomethacin–induced Scar Thinning After Experimental Myocardial Infarction

  1983cited by this paper
• Scar thinning due to ibuprofen administration after experimental myocardial infarction.

  1983cited by this paper
• Editorial: The End‐systolic Pressure‐Volume Relation of the Ventricle Definition, Modifications and Clinical Use

  1981cited by this paper
• The end-systolic pressure-volume relation of the ventricle: definition, modifications and clinical use.

  1981cited by this paper
• Downloaded from http://circres.ahajournals.org / by guest on February 21, 2013Gene Therapy With Inducible Nitric Oxide Synthase Protects Against Myocardial Infarction via a Cyclooxygenase-2–Dependent Mechanism

  year unknowncited by this paper

• Early-age efferocytosis directs macrophage arachidonic acid metabolism for tissue regeneration.

  2025cites this paper
• Cardioprotective strategies in myocardial ischemia-reperfusion injury: Implications for improving clinical translation

  2024cites this paper
• Emerging Roles and Therapeutic Applications of Arachidonic Acid Pathways in Cardiometabolic Diseases

  2024cites this paper
• Prostanoids in Cardiac and Vascular Remodeling

  2024cites this paper
• Macrophage heterogeneity in myocardial infarction: Evolution and implications for diverse therapeutic approaches

  2024cites this paper
• The role of COX2 deficiency attenuates cardiac damage in acute myocardial infarction

  2024cites this paper
• Targeting neuro-immune systems to achieve cardiac tissue repair following myocardial infarction: A review of therapeutic approaches from in-vivo preclinical to clinical studies

  2023cites this paper
• Pollutants in aquatic system: a frontier perspective of emerging threat and strategies to solve the crisis for safe drinking water

  2023cites this paper
• Microsomal prostaglandin E synthase‐1 inhibition prevents adverse cardiac remodelling after myocardial infarction in mice

  2023cites this paper
• Inflammation in Myocardial Ischemia/Reperfusion Injury: Underlying Mechanisms and Therapeutic Potential

  2023cites this paper
• MicroRNA profiling of the feline left heart identifies chamber-specific expression signatures in health and in advanced hypertrophic cardiomyopathy

  2023cites this paper
• Effects of Hypertrophic and Dilated Cardiac Geometric Remodeling on Ejection Fraction

  2022cites this paper
• Hydrogel-load exosomes derived from dendritic cells improve cardiac function via Treg cells and the polarization of macrophages following myocardial infarction

  2021cites this paper
• Role of prostaglandin E2 in allogeneic mesenchymal stem cell therapy for cardiac repair.

  2021cites this paper
• Celecoxib alleviates pathological cardiac hypertrophy and fibrosis via M1-like macrophage infiltration in neonatal mice

  2021cites this paper
• Immediate Renal Denervation After Acute Myocardial Infarction Mitigates the Progression of Heart Failure via the Modulation of IL-33/ST2 Signaling

  2021cites this paper
• Role of prostaglandin E2 in tissue repair and regeneration

  2021cites this paper
• CUPS to Manage Pericarditis

  2021cites this paper
• Interplay Between Oxidative Stress, Cyclooxygenases, and Prostanoids in Cardiovascular Diseases

  2020cites this paper
• Cardiovascular effects and safety of (non-aspirin) NSAIDs

  2020cites this paper
• Cardiovascular Biology of Prostanoids and Drug Discovery.

  2020cites this paper
• Systemic Mesenchymal Stem Cell-Derived Exosomes Reduce Myocardial Infarct Size: Characterization With MRI in a Porcine Model

  2020cites this paper
• Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion

  2020cites this paper
• Using proximity extension proteomics assay to identify biomarkers associated with infarct size and ejection fraction after ST-elevation myocardial infarction

  2020cites this paper
• Biphasic changes in TGF-β1 signaling drive NSAID-induced multi-organ damage.

  2020cites this paper
• Cardio-renal safety of non-steroidal anti-inflammatory drugs.

  2019cites this paper
• The cyclooxygenase-1/mPGES-1/endothelial prostaglandin EP4 receptor pathway constrains myocardial ischemia-reperfusion injury

  2019cites this paper
• Mesenchymal stromal cell-derived exosomes attenuate myocardial ischaemia-reperfusion injury through miR-182-regulated macrophage polarization

  2019cites this paper
• MicroRNA-26b relieves inflammatory response and myocardial remodeling of mice with myocardial infarction by suppression of MAPK pathway through binding to PTGS2.

  2019cites this paper
• HMGB1 and repair: focus on the heart

  2019cites this paper
• Diclofenac use and cardiovascular risks: series of nationwide cohort studies

  2018cites this paper
• Anti‐inflammatory therapies in myocardial infarction: failures, hopes and challenges

  2018influential citation
• The adaptive immune response to cardiac injury—the true roadblock to effective regenerative therapies?

  2017cites this paper
• Molecular mechanisms of cardioprotective effects mediated by transplanted cardiac ckit+ cells through the activation of an inflammatory hypoxia-dependent reparative response

  2017cites this paper
• NSAID Use and Cardiovascular Disease - A Cautionary Tale.

  2017cites this paper
• Flow dynamics and energy efficiency of flow in the left ventricle during myocardial infarction

  2017cites this paper
• Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology.

  2016cites this paper
• Borage oil attenuates progression of cardiac remodeling in rats after myocardial infarction.

  2016cites this paper
• Translational failure of anti-inflammatory compounds for myocardial infarction: a meta-analysis of large animal models.

  2016cites this paper
• Celecoxib for the treatment of atherosclerosis

  2016cites this paper
• Clinical Pharmacology and Cardiovascular Safety of Naproxen

  2016cites this paper
• Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology.

  2016cites this paper
• Effects of Indomethacin on Intracellular pH and Na⁺/H⁺ Exchanger in the Human Monocytes.

  2015cites this paper
• BLT1 antagonist LSN2792613 reduces infarct size in a mouse model of myocardial ischaemia-reperfusion injury.

  2015cites this paper
• The impact of NSAID treatment on cardiovascular risk - insight from Danish observational data.

  2014cites this paper
• Anti-inflammatory strategies for ST-elevation acute myocardial infarction ventricular remodeling

  2014cites this paper
• Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction.

  2014cites this paper
• Dual effect of inflammation and regulation of bone marrow mesenchymal cells on myocardial infarction tissue

  2014cites this paper
• Endogenous Prostaglandin D2 and Its Metabolites Protect the Heart Against Ischemia–Reperfusion Injury by Activating Nrf2

  2014cites this paper
• Diverse stage-dependent effects of glucocorticoids in a murine model of viral myocarditis.

  2013cites this paper
• The effects of cyclooxygenase and nitric oxide synthase inhibition on cardiodynamic parameters and coronary flow in isolated rat hearts.

  2013cites this paper
• Stem Cells and Healing: Impact on Inflammation

  2013cites this paper
• Cardiac consequences of anti-inflammatory drugs in experimental models.

  2013cites this paper
• The effects of cyclooxygenase and nitric oxide synthase inhibition on oxidative stress in isolated rat heart

  2013cites this paper
• Mitigating the cardiovascular and renal effects of NSAIDs.

  2013cites this paper
• Cardiac stem cell therapy to modulate inflammation upon myocardial infarction.

  2013cites this paper
• Medical management of acute pain in patients with chronic pain

  2012cites this paper
• The innate immune response in reperfused myocardium.

  2012cites this paper
• Post-infarct cardiac rupture: recent insights on pathogenesis and therapeutic interventions.

  2012cites this paper
• Lack of Microsomal Prostaglandin E2 Synthase-1 in Bone Marrow–Derived Myeloid Cells Impairs Left Ventricular Function and Increases Mortality After Acute Myocardial Infarction

  2012cites this paper
• Patients With ST-Elevation Myocardial Infarction : 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of

  2012cites this paper
• Effect of hepatocyte growth factor and angiotensin II on rat cardiomyocyte hypertrophy

  2012influential citation
• Surgical left ventricular radius enlargement by patch insertion on the beating heart: a new experimental aneurysm model.

  2012cites this paper
• Remodelling and adverse remodelling in CAD

  2012cites this paper
• Do we know enough about the immune pathogenesis of acute coronary syndromes to improve clinical practice?

  2012cites this paper
• Competitive Enzymatic Interactions Determine the Relative Amounts of Prostaglandins E2 and D2

  2011cites this paper
• Inflammasome activation in reperfusion injury: friendly fire on myocardial infarction?

  2011cites this paper
• HIGHLIGHTED TOPIC Mechanism of Beneficial Effects of Physical Activity on Atherosclerosis and Coronary Heart Disease Ca regulatory mechanisms of exercise protection against coronary artery disease in metabolic syndrome and diabetes

  2011cites this paper
• Ca2+ regulatory mechanisms of exercise protection against coronary artery disease in metabolic syndrome and diabetes.

  2011cites this paper
• Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction.

  2011cites this paper
• New targets to treat the structural remodeling of the myocardium.

  2011cites this paper
• Mechanism of Beneficial Effects of Physical Activity on Atherosclerosis and Coronary Heart Disease Ca 2 regulatory mechanisms of exercise protection against coronary artery disease in metabolic syndrome and diabetes

  2011cites this paper
• Compensatory hypertrophy induced by ventricular cardiomyocyte-specific COX-2 expression in mice.

  2010cites this paper
• The I&kgr;B Kinase Inhibitor Nuclear Factor-&kgr;B Essential Modulator–Binding Domain Peptide for Inhibition of Injury-Induced Neointimal Formation

  2010cites this paper
• A novel vascularized patch enhances cell survival and modifies ventricular remodeling in a rat myocardial infarction model.

  2010cites this paper
• Reduction of infarct size by gentle reperfusion without activation of reperfusion injury salvage kinases in pigs.

  2010cites this paper
• Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2.

  2010cites this paper
• CHAPTER 13 – Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction

  2010cites this paper
• Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone

  2010cites this paper
• Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals

  2010cites this paper
• Pathophysiology of Cyclooxygenases in Cardiovascular Homeostasis

  2010cites this paper
• Constitutive COX-2 activity in cardiomyocytes confers permanent cardioprotection Constitutive COX-2 expression and cardioprotection.

  2009cites this paper
• Actualización en cardiopatía isquémica

  2009cites this paper
• Prähospitales Management des ST-Strecken-Hebungsinfarktes

  2009cites this paper
• Targeted Deletion of Nuclear Factor &kgr;B p50 Enhances Cardiac Remodeling and Dysfunction Following Myocardial Infarction

  2009cites this paper
• Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure.

  2009cites this paper
• Guías de Práctica Clínica de la Sociedad Europea de Cardiología (ESC). Manejo del infarto agudo de miocardio en pacientes con elevación persistente del segmento ST

  2009cites this paper
• The Journal of Toxicological Sciences

  2009cites this paper
• Selective Cyclooxygenase-2 Inhibition Protects Against Myocardial Damage in Experimental Acute Ischemia

  2009cites this paper
• Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.

  2009cites this paper
• Cardiac Function After Myocardial Infarction Toll-Like Receptor 4 Mediates Maladaptive Left Ventricular Remodeling and Impairs

  2008cites this paper
• [Ischemic heart disease: update].

  2008cites this paper
• Cardiac remodelling hinders activation of cyclooxygenase-2, diminishing protection by delayed pharmacological preconditioning: role of HIF1 alpha and CREB.

  2008cites this paper
• Pleiotropic effects of cardiac drugs on healing post-MI. The good, bad, and ugly

  2008cites this paper
• Cardiac remodelling hinders activation of cyclooxygenase-2 , diminishing protection by delayed pharmacological preconditioning : role of HIF 1 alpha and CREB

  2008cites this paper
• 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2008influential citation
• Microsomal Prostaglandin E2 Synthase-1 Deletion Leads to Adverse Left Ventricular Remodeling After Myocardial Infarction

  2008cites this paper
• 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2008cites this paper
• Toll-Like Receptor 4 Mediates Maladaptive Left Ventricular Remodeling and Impairs Cardiac Function After Myocardial Infarction

  2008cites this paper
• Potential novel pharmacological therapies for myocardial remodelling.

  2008influential citation